SCHEMBL5465690

SCHEMBL5465690

CCOC(=O)c1cc2n[nH]c(=O)n2c2ccccc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 4/20 0.61
KDM4E B2RXH2 10/20 0.50
ALDH1A1 P00352 4/20 0.50
GAA P10253 3/20 0.50
KMT2A Q03164 3/20 0.50
MEN1 O00255 2/20 0.50
NPSR1 Q6W5P4 2/20 0.50
MAPT P10636 1/20 0.50
HPGD P15428 3/20 0.47
RAB9A P51151 1/20 0.47
HIF1A Q16665 1/20 0.47
POLB P06746 2/20 0.47
GLA P06280 1/20 0.45
ADORA3 P0DMS8 1/20 0.45
TSHR P16473 2/20 0.44
ALOX15 P16050 1/20 0.44
ATM Q13315 1/20 0.44
HSD17B10 Q99714 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5470789 0.87 CHEK1 (0.47) CHEK1KDM4EALDH1A1GAAKMT2A
SCHEMBL5478071 0.85 LMNA (0.52) CHEK1ALDH1A1KMT2AMEN1MAPT
SCHEMBL5480737 0.85 CHEK1 (0.58) CHEK1ALDH1A1LMNA
SCHEMBL5470116 0.84 CHEK1 (0.50) CHEK1KDM4EALDH1A1GAAKMT2A
SCHEMBL5470798 0.76 CHEK1 (1.00) CHEK1
SCHEMBL14492135 0.73 CHEK1 (0.60) CHEK1
SCHEMBL5470155 0.72 CHEK1 (0.70) CHEK1RAB9A
SCHEMBL5483336 0.71 CHEK1 (0.68) CHEK1RAB9A
SCHEMBL5478918 0.70 CHEK1 (0.67) CHEK1HSD17B10
SCHEMBL7215714 0.70 TSHR (0.54) KDM4EALDH1A1GAAKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070149560-A1 Novel fused triazolones and the uses thereof ASTRAZENECA AB (SE) 2007-06-28 US claimed
JP-2006520397-A 2006-09-07 JP claimed
EP-1613625-A1 NOVEL FUSED TRIAZOLONES AND THE USES THEREOF AstraZeneca AB (SE) 2006-01-11 EP claimed
WO-2004081008-A1 NOVEL FUSED TRIAZOLONES AND THE USES THEREOF ASTRAZENECA AB (SE) 2004-09-23 WO claimed
US-20070149560-A1 Novel fused triazolones and the uses thereof ASTRAZENECA AB (SE) 2007-06-28 US disclosed
EP-1613625-A1 NOVEL FUSED TRIAZOLONES AND THE USES THEREOF AstraZeneca AB (SE) 2006-01-11 EP disclosed
WO-2004081008-A1 NOVEL FUSED TRIAZOLONES AND THE USES THEREOF ASTRAZENECA AB (SE) 2004-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149560-A1 Novel fused triazolones and the uses thereof TP53, BRCA1, KLK3 CHEK1 13/4885KDM4E 3368/4885ALDH1A1 1270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.